R&D Trends

University of Cambridge, Elan launch research center

Monday, November 28, 2011 03:21 PM

The University of Cambridge and Elan have launched The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University of Cambridge, England. The Cambridge-Elan Centre will provide an interdisciplinary environment uniquely positioned for delivering translational research focused on innovative therapies for Alzheimer's and Parkinson's diseases. This ten-year agreement paves the way for a long-term collaboration between Elan and the University of Cambridge.

More... »

Roche, BGI develop advanced MHC technology

Monday, November 28, 2011 11:47 AM

More... »

MGH, Vall d'Hebron Hospital partner with BBVA Foundation in biomarker research

Wednesday, November 23, 2011 10:47 AM

The BBVA Foundation has reported an agreement to underwrite a joint effort between Massachusetts General Hospital and Barcelona's Vall d'Hebron Hospital to search for personalized cancer therapies through biomarker research.

More... »

U-M Medical School, MedImmune ink 3 year research agreement

Wednesday, November 23, 2011 09:42 AM

Leaders from the University of Michigan Medical School and MedImmune, the global biologics arm of AstraZeneca, have signed a new agreement to work together on a broad range of projects. The three-year strategic collaboration will bring scientists from one of the nation’s top medical research institutions together with scientists from one of the world’s leading developers of biologic therapies. UMMS and MedImmune scientists will cooperate on studies that aim to translate scientific discoveries from the laboratory into new candidates for treating cancer, heart disease, digestive disease, lung disease and diseases caused by inflammation.

More... »

Researchers discover new drug combo targeting multiple cancers

Tuesday, November 22, 2011 12:11 PM

Researchers at the University of California, San Diego School of Medicine and Kyushu University Medical School say a novel combination of a specific sugar molecule with a pair of cell-killing drugs prompts a wide variety of cancer cell types to kill themselves, a process called apoptosis or programmed cell death. The findings are reported online in the journal Cancer Research.

More... »

Lilly awards IDRI $4 million in tuberculosis research funding

Tuesday, November 22, 2011 10:55 AM

The Infectious Disease Research Institute (IDRI) has been awarded more than $4 million in additional funding over the next four and a half years by Eli Lilly. The funding will support IDRI’s continued early phase drug discovery research, which focuses on the identification of effective new therapies in the fight against tuberculosis (TB), including multidrug-resistant TB (MDR-TB).

More... »

EFPIA launches strategy to revitalize antibiotic research

Friday, November 18, 2011 10:41 AM

EFPIA, the voice of the research-based pharmaceutical industry in Europe, welcomes the publication of the European Commission's "Strategy and Action Plan to Tackle the Threat of Antibiotic Resistance".

More... »

Tufts CSDD receives research grant from goBalto

Thursday, November 17, 2011 02:49 PM

San Francisco-based goBalto, a developer of new generation web-based clinical research solutions, is providing a research grant for the Tufts Center for the Study of Drug Development to benchmark the clinical trial initiation process. Currently there is virtually no industry data available on the typical process that companies follow and on the amount of time that this process takes.

More... »

Cenix, SYGNIS sign RNAi research agreement

Thursday, November 17, 2011 02:02 PM

Cenix BioScience, a discovery-stage contract research provider and technology developer, has signed a research agreement with SYGNIS Bioscience, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.

More... »

Genzyme, Cystic Fibrosis Foundation Therapeutics ink research agreement

Wednesday, November 16, 2011 02:33 PM

Genzyme, a Sanofi company, and Cystic Fibrosis Foundation Therapeutics, the nonprofit affiliate of the Cystic Fibrosis Foundation, have signed a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.

More... »